Der Konsensusreport 2009 zur allergenspezifischen Immuntherapie (AIT) bei IgE-vermittelten (Ig: Immunglobulin) allergischen Erkrankungen im Kindes- und Jugendalter ist aufgrund zunehmend größerer Angebote an Allergenpräparaten und der sehr heterogenen Studienlage entstanden. Mittlerweile erfährt die Landschaft der Immuntherapie eine deutliche Umgestaltung (Verordnung der Europäischen Union [EU], Therapie-Allergene-Verordnung etc.). Geblieben ist die ethische Verpflichtung, Kinder und Jugendliche möglichst mit Allergenpräparaten zu behandeln, die auch in Studien an Kindern und Jugendlichen geprüft sowie als wirksam und sicher eingestuft worden sind (EU-Regulative, European Medicines Agency [EMA]). Die 2017 aktualisierte, für Österreich geltende Liste der Immuntherapiepräparate mit besonderem Bezug zu Kindern und Jugendlichen wurde nunmehr angepasst. Eine kritische Betrachtung der Studienlandschaft wurde abermals verfolgt. Einige neu auf den Markt gekommene Immuntherapieprodukte zeigen eine verbesserte Datenlage aus Studien, die ausschließlich an Kindern und Jugendlichen durchgeführt wurden. Daher können diese zugelassenen und lizensierten Produkte zur indikationsgerechten Verwendung bei Kindern und Jugendlichen empfohlen werden. ; The consensus report from 2009 on allergen-specific immunotherapy for immunoglobulin E (IgE) mediated allergic diseases in childhood and adolescence was issued due to the increasingly large offer of allergen preparations and the heterogeneous state of studies. The field of immunotherapy has now undergone a clear restructuring (Regulations of the European Union [EU], Therapy-Allergens Regulations etc.). There remains the ethical obligation to treat children and adolescents with allergen preparations, which were also tested in studies including children and adolescents and were classified as being effective and safe (EU regulative, European Medicines Agency [EMA]). The updated list from 2017 of immunotherapy preparations with particular reference to children and adolescents valid for Austria has now been adapted. A critical appraisal of the study situation has been carried out again. Some immunotherapy products which have recently come onto the market show an improved dataset from studies that were carried out exclusively on children and adolescents. These approved and licensed products can therefore be recommended for indications-compliant administration to children and adolescents.
Der Konsensusreport 2009 zur allergenspezifischen Immuntherapie (AIT) bei Immunglobulin(Ig)E-vermittelten allergischen Erkrankungen im Kindes- und Jugendalter ist aufgrund zunehmend größerer Angebote an Allergenpräparaten und der sehr heterogenen Studienlage entstanden. Mittlerweile erfährt die Landschaft der Immuntherapie eine deutliche Umgestaltung (Verordnung der Europäischen Union [EU], Therapie-Allergene-Verordnung etc.). Geblieben ist die ethische Verpflichtung, Kinder und Jugendliche möglichst mit Allergenpräparaten zu behandeln, die auch in Studien an Kindern und Jugendlichen geprüft sowie als wirksam und sicher eingestuft worden sind (EU-Regulative, European Medicines Agency [EMA]). Die 2017 aktualisierte, für Österreich geltende Liste der Immuntherapiepräparate mit besonderem Bezug zu Kindern und Jugendlichen wurde nunmehr angepasst. Eine kritische Betrachtung der Studienlandschaft wurde abermals verfolgt. Einige neu auf den Markt gekommene Immuntherapieprodukte zeigen eine verbesserte Datenlage aus Studien, die ausschließlich an Kindern und Jugendlichen durchgeführt wurden. Daher können diese zugelassenen und lizensierten Produkte zur indikationsgerechten Verwendung bei Kindern und Jugendlichen empfohlen werden. ; The consensus report from 2009 on allergen-specific immunotherapy for immunoglobulin E (IgE) mediated allergic diseases in childhood and adolescence was issued due to the increasingly large offer of allergen preparations and the heterogeneous state of studies. The field of immunotherapy has now undergone a clear restructuring (regulations of the European Union [EU], therapy allergen regulations etc.). There remains the ethical obligation to treat children and adolescents with allergen preparations, which were also tested in studies including children and adolescents and were classified as being effective and safe (EU regulative, European Medicines Agency [EMA]). The updated list of immunotherapy preparations from 2017 with particular reference to children and adolescents valid for Austria has now been adapted. A critical reappraisal of the study situation has been carried out. Some immunotherapy products which have recently come onto the market show an improved dataset from studies that were carried out exclusively on children and adolescents. These approved and licensed products can therefore be recommended for indication-compliant administration to children and adolescents.
In: Bonertz , A , Roberts , G , Slater , J E , Bridgewater , J , Rabin , R L , Hoefnagel , M , Timon , M , Pini , C , Pfaar , O , Sheikh , A , Ryan , D , Akdis , C , Goldstein , J , Poulsen , L K , van Ree , R , Rhyner , C , Barber , D , Palomares , O , Pawankar , R , Hamerlijnk , D , Klimek , L , Agache , I , Angier , E , Casale , T , Fernandez-Rivas , M , Halken , S , Jutel , M , Lau , S , Pajno , G , Sturm , G , Varga , E M , van Wijk , R G , Bonini , S , Muraro , A & Vieths , S 2018 , ' Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States : An analysis from the EAACI AIT Guidelines Project ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 73 , no. 4 , pp. 816-826 . https://doi.org/10.1111/all.13357
Adequate quality is essential for any medicinal product to be eligible for marketing. Quality includes verification of the identity, content and purity of a medicinal product in combination with a specified production process and its control. Allergen products derived from natural sources require particular considerations to ensure adequate quality. Here, we describe key aspects of the documentation on manufacturing and quality aspects for allergen immunotherapy products in the European Union and the United States. In some key parts, requirements in these areas are harmonized while other fields are regulated separately between both regions. Essential differences are found in the use of Reference Preparations, or the requirement to apply standardized assays for potency determination. As the types of products available are different in specific regions, regulatory guidance for such products may also be available in one specific region only, such as for allergoids in the European Union. Region-specific issues and priorities are a result of this. As allergen products derived from natural sources are inherently variable in their qualitative and quantitative composition, these products present special challenges to balance the variability and ensuring batch-to-batch consistency. Advancements in scientific knowledge on specific allergens and their role in allergic disease will consequentially find representation in future regulatory guidelines.
In: Bonertz , A , Roberts , G C , Hoefnagel , M , Timon , M , Slater , J E , Rabin , R L , Bridgewater , J , Pini , C , Pfaar , O , Akdis , C , Goldstein , J , Poulsen , L K , van Ree , R , Rhyner , C , Barber , D , Palomares , O , Sheikh , A , Pawankar , R , Hamerlijnk , D , Klimek , L , Agache , I , Angier , E , Casale , T , Fernandez-Rivas , M , Halken , S , Jutel , M , Lau , S , Pajno , G , Sturm , G , Varga , E M , Gerth van Wijk , R , Bonini , S , Muraro , A & Vieths , S 2018 , ' Challenges in the implementation of EAACI guidelines on allergen immunotherapy : A global perspective on the regulation of allergen products ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 73 , no. 1 , pp. 64–76 . https://doi.org/10.1111/all.13266
Regulatory approaches for allergen immunotherapy (AIT) products and the availability of high-quality AIT products are inherently linked to each other. While allergen products are available in many countries across the globe, their regulation is very heterogeneous. First, we describe the regulatory systems applicable for AIT products in the European Union (EU) and in the United States (US). For Europe, a depiction of the different types of relevant procedures, as well as the committees involved, is provided and the fundamental role of national agencies of the EU member states in this complex and unique network is highlighted. Furthermore, the regulatory agencies from Australia, Canada, Japan, Russia, and Switzerland provided information on the system implemented in their countries for the regulation of allergen products. While AIT products are commonly classified as biological medicinal products, they are made available by varying types of procedures, most commonly either by obtaining a marketing authorization or by being distributed as named patient products. Exemptions from marketing authorizations in exceptional cases, as well as import of allergen products from other countries, are additional tools applied by countries to ensure availability of needed AIT products. Several challenges for AIT products are apparent from this analysis and will require further consideration.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon ; Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England ; UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France ; Univ S Florida, Morsani Coll Med, Tampa, FL USA ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland ; Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium ; IQ4U Consultants Ltd, London, England ; Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy ; Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria ; Univ Naples 2, Rome, Italy ; CNR, IFT, Rome, Italy ; Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy ; Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain ; Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France ; Nova Southeastern Univ, Ft Lauderdale, FL USA ; Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France ; Univ Versailles St Quentin, Suresnes, France ; Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France ; Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France ; Univ Palermo, Di Bi MIS, Palermo, Italy ; Kings Coll London, Guys & St Thomas NHS Trust, London, England ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England ; Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland ; Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy ; Kings Coll London, Allergy Acad, London, England ; Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands ; Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina ; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland ; Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark ; Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium ; Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark ; UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France ; Hosp Sirio Libanes, Sao Paulo, Brazil ; Univ Hosp Montpellier, Montpellier, France ; UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France ; Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany ; German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands ; Med Univ Lodz, Lodz, Poland ; ARIA, Mexico City, DF, Mexico ; Hosp Med Sur, AAAAI, Mexico City, DF, Mexico ; Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark ; Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark ; Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark ; Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany ; Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark ; Klinikum Univ Koln AoR, IMSIE, Cologne, Germany ; Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain ; Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece ; Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ; ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy ; Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany ; Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany ; Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland ; RiRL, Cambridge, England ; Optimum Patient Care Ltd, Singapore, Singapore ; Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain ; Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; Royal Natl Throat Nose & Ear Hosp, London, England ; UCL, London, England ; Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England ; MRC, London, England ; Asthma UK Ctr Allerg Mechanisms Asthma, London, England ; Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland ; SLAAI, Asuncion, Paraguay ; Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil ; Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria ; Allergy Outpatient Clin Reumannplatz, Vienna, Austria ; Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain ; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands ; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands ; Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy ; Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain ; Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria ; Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany ; European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France ; INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France ; Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France ; CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France ; Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil ; Web of Science
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , Del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , Van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; Peer reviewed
In: Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T. and Bousquet, J. (2016). Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clin. Transl. Allergy, 6. LONDON: BMC. ISSN 2045-7022
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : From research to policies ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
